In the context of AML, whether combining MIF inhibitor with proinflammatory agonists, such as granulocyte-macrophage colony-stimulating factor (GM-CSF), which was demonstrated to be very effective in combination with CSF1R inhibition [18, 21], reprograms MΦ to an antitumoral phenotype, was not determined. The gene discussed is CSF2; the disease is acute myeloid leukemia.